Filament Health Corp. (FLHLF)
| Previous Close | 0.0000 |
| Open | 0.0400 |
| Bid | 0.0285 x 0 |
| Ask | 0.0435 x 0 |
| Day's Range | 0.0400 - 0.0400 |
| 52 Week Range | 0.0212 - 0.1544 |
| Volume | |
| Avg. Volume | 10,144 |
| Market Cap | 11.529M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupFILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024.
CNW GroupFILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has expanded its intellectual property (IP) portfolio with the acceptance of twelve patents by IP Australia for processes relating to the development of botanical psychedelic drugs. Filament has been issued a further five patents by the Canadian Intellectual Property Office (CIPO), and three patents by the United State
- Newsfile
Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the "Acquiror"), a shareholder of Filament Health Corp. ("Filament"), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the "Common Shares") from the conversion of a convertible note due July 13, 2024 ("Note") and the exercise of the Acquiror's outstanding warrants ("Warrants") to purchase Common Shares (collectively, the "Transaction"). In connection with the Transact
